# EDGAR Filing Document

**Accession Number:** 0001623715
**File Stem:** 0001193125-23-006153
**Filing Date:** 2023-1
**Character Count:** 7208
**Document Hash:** 22b6b8dab51e12de656634fe0580c305
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-006153.hdr.sgml**: 20230111

**ACCESSION NUMBER**: 0001193125-23-006153

**CONFORMED SUBMISSION TYPE**: POS AM

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230111

**DATE AS OF CHANGE**: 20230111

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Imago BioSciences, Inc.
- **CENTRAL INDEX KEY:** 0001623715
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 454915810
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POS AM
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-266963
- **FILM NUMBER:** 23522667

**BUSINESS ADDRESS:**
- **STREET 1:** 303 TWIN DOLPHIN DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** (415) 529-5055

**MAIL ADDRESS:**
- **STREET 1:** 303 TWIN DOLPHIN DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**As filed with the Securities and Exchange Commission on January 11, 2023** 

**Registration No. 333-266963** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**POST-EFFECTIVE AMENDMENT NO. 1** 

**TO** 

**FORM S-3** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

------

## IMAGO BIOSCIENCES, INC.
**(Exact name of registrant as specified in its charter)** 

------

---

| | |
|:---|:---|
| **Delaware**  | **45-4915810**  |
| **(State or other jurisdiction of incorporation)** | **(I.R.S. Employer Identification Number)** |

---

**303 Twin Dolphin Drive, 6th Floor** 

**Redwood City, California 94065** 

**(415) 529-5055** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

------

**Kelly E.W. Grez, Secretary** 

**Imago BioSciences, Inc.** 

**303 Twin Dolphin Drive, 6th Floor** 

**Redwood City, California 94065** 

**(415) 529-5055** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

------

***Copy to:***

**Saee Muzumdar** 

**Gibson, Dunn & Crutcher LLP** 

**200 Park Avenue** 

**New York, NY 10166-0193** 

**(212) 351-4035** 

------

**Approximate date of commencement of proposed sale to the public**: Not Applicable. Removal from registration of securities that were not sold pursuant to the above referenced registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**<u>TERMINATION OF REGISTRATION</u>**

This Post-Effective Amendment No. 1 relates to the following Registration Statement on Form S-3 (the "Registration Statement") filed by Imago BioSciences, Inc. (the "Company") with the Securities and Exchange Commission:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Registration No. 333-266963, filed on August 18, 2022 and
declared effective on August 29, 2022, registering (i) common stock, preferred stock, depositary shares, warrants, purchase contracts and units, up to a maximum aggregate offering price of $400,000,000 and (ii) common stock up to a
maximum aggregate offering price of $150,000,000.

Pursuant to the Agreement and Plan of Merger, dated as of November 19, 2022 (the "Merger Agreement"), by and among the Company, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and M-Inspire Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Company has terminated all offerings of its securities pursuant to the Registration Statement and hereby removes and withdraws from registration all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rahway, in the State of New Jersey, on this 11th day of January, 2023.

---

| | |
|:---|:---|
| **IMAGO BIOSCIENCES, INC. (REGISTRANT)** | **IMAGO BIOSCIENCES, INC. (REGISTRANT)** |
| By: | /s/ Kelly E.W. Grez |
| Name: | Kelly E.W. Grez |
| Title: | Secretary |

---

Pursuant to the Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment No. 1 to Registration Statement.